Minerva Neurosciences (NERV) Non-Current Assets (2013 - 2026)
Minerva Neurosciences' (NERV) quarterly Non-Current Assets came in at $14.9 million in Q1 2026, little changed YoY from $14.9 million in Q1 2025, and little changed on a QoQ basis from $14.9 million in Q4 2025.
Analysis
Minerva Neurosciences (NERV) Non-Current Assets (2013 - 2026) Analysis & Trends
Minerva Neurosciences (NERV) has 14 years of Non-Current Assets data on file, last reported at $14.9 million in Q1 2026.
- Quarterly Non-Current Assets changed 0.32% year-over-year to $14.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.7 million (changed 0.38% YoY) and the FY2025 annual result came in at $14.9 million, changed 0.04% from the prior year.
- Non-Current Assets steadied at $14.9 million in Q1 2026, from $14.9 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $15.1 million in Q3 2025 to a low of $14.9 million in Q4 2025.
- A 5-year average of $14.9 million and a median of $14.9 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets tumbled 50.5% — and 2025, when it rose 1.32%.
- Tracing NERV's Non-Current Assets over 5 years: stood at $14.9 million in 2022, then slipped by 0.21% to $14.9 million in 2023, then retreated by 0.15% to $14.9 million in 2024, then retreated by 0.04% to $14.9 million in 2025, then increased by 0.34% to $14.9 million in 2026.
- The last three Non-Current Assets figures came in at $14.9 million (Q1 2026), $14.9 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.15 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 294.93 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 18.06 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - | 15.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.36 Mn |
| Mar 31, 2026 | 14.92 Mn |
| Dec 31, 2025 | 14.87 Mn |
| Sep 30, 2025 | 15.07 Mn |
| Jun 30, 2025 | 14.87 Mn |
| Mar 31, 2025 | 14.87 Mn |
| Dec 31, 2024 | 14.87 Mn |
| Sep 30, 2024 | 14.88 Mn |
| Jun 30, 2024 | 14.88 Mn |
| Mar 31, 2024 | 14.89 Mn |
| Dec 31, 2023 | 14.90 Mn |
| Sep 30, 2023 | 14.91 Mn |
| Jun 30, 2023 | 14.91 Mn |
| Mar 31, 2023 | 14.92 Mn |
| Dec 31, 2022 | 14.93 Mn |
| Sep 30, 2022 | 14.92 Mn |
| Jun 30, 2022 | 14.92 Mn |
| Mar 31, 2022 | 14.92 Mn |
| Dec 31, 2021 | 14.92 Mn |
| Sep 30, 2021 | 30.12 Mn |